<DOC>
	<DOC>NCT01135433</DOC>
	<brief_summary>This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and metformin in patients with diabetes mellitus.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients</brief_title>
	<detailed_description>This study is to evaluate the efficacy (HbA1c change from baseline) and safety of ASP1941 in combination with metformin in subjects with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with metformin alone. The effects of ASP1941 are compared with those of placebo.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetic patients receiving with metformin monotherapy for at least 6 weeks HbA1c value between 7.0 and 9.5% Body Mass Index (BMI) 20.0 45.0 kg/m2 Type 1 diabetes mellitus patients Serum creatinine &gt; upper limit of normal Estimated GFR &lt; 60ml/min/1.73m2 Proteinuria (albumin/creatinine ratio &gt; 300mg/g) Dysuria and/or urinary tract infection, genital infection Significant renal, hepatic or cardiovascular diseases Severe gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Metformin</keyword>
</DOC>